Bupropion Use for Adjuvant Analgesia in a Patient with Fibromyalgia: A Case ReportAdam Gummersheimer1, Tabetha Todd1 and Christopher M. Herndon2*
- *Corresponding Author:
- Christopher M. Herndon
Associate Professor, School of Pharmacy
Advanced Practice Pharmacist, Scott Air Force Base
Southern Illinois University Edwardsville
200 University Park Drive, Box 2000, Edwardsville, USA
E-mail: [email protected]
Received date: January 08, 2016 Accepted date: February 28, 2016 Published date: March 02, 2016
Citation: Gummersheimer A, Todd T and Herndon CM (2016) Bupropion Use for Adjuvant Analgesia in a Patient with Fibromyalgia: A Case Report. Fibrom Open Access 1: 106. doi:10.4172/foa.1000106
Copyright: © 2016 Gummersheimer A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Fibromyalgia is a chronic syndrome characterized by widespread pain, fatigue, gastrointestinal disturbances, neurocognitive dulling, and insomnia. Currently, three medications are approved for fibromyalgia by the United States Food and Drug Administration (FDA): pregabalin, duloxetine, and milnacipran. This case study reviews the use of bupropion as a potential co-analgesic in patients with refractory fibromyalgia. Previous studies have assessed the use of dopamine agonists in the treatment of fibromyalgia with both ropinirole and pramipexole exhibiting efficacy. Bupropion, an atypical antidepressant with noradrenergic and dopaminergic modulatory effects, may theoretically provide similar efficacy in patients with fibromyalgia syndrome.